What are the causes of elevated monocytes (monocytosis)?

Causes of Elevated Monocytes (Monocytosis)

Elevated monocytes are most commonly caused by reactive/secondary conditions (infections, inflammation, malignancy), but when persistent without identifiable cause, require investigation for clonal hematologic disorders, particularly chronic myelomonocytic leukemia (CMML).

Primary Diagnostic Framework

The evaluation of monocytosis follows a hierarchical approach based on whether a secondary cause is identifiable:

Reactive (Secondary) Causes - Most Common

The vast majority of monocytosis cases are secondary to underlying conditions 1, 2, 3:

• Infections - bacterial, viral, fungal, parasitic
• Inflammatory conditions - autoimmune diseases, inflammatory bowel disease
• Solid tumors - various malignancies can trigger reactive monocytosis
• Recovery from bone marrow suppression - post-chemotherapy, post-infection
• Chronic inflammatory states - sarcoidosis, vasculitis

These cases typically present with identifiable clinical context and/or biological inflammatory markers 4.

Clonal (Primary) Causes - Require Exclusion When Persistent

When monocytosis persists (≥3 months) without identifiable reactive cause, clonal hematologic disorders must be considered 5:

Chronic Myelomonocytic Leukemia (CMML) - The Prototypical Disorder

CMML is defined by specific WHO criteria 5:

• Persistent peripheral blood monocytosis (>1×10⁹/L)
• No Philadelphia chromosome or BCR-ABL1 fusion gene
• No PDGFRA or PDGFRB rearrangement (must exclude in eosinophilia cases)
• <20% blasts in peripheral blood and bone marrow
• Plus at least one of:
  • Dysplasia in ≥1 cell lineage
  • Acquired clonal cytogenetic/molecular abnormality
  • Monocytosis persisting ≥3 months with no other identifiable cause

Other Myeloid Neoplasms

• Myelodysplastic syndromes (MDS) - particularly refractory cytopenia with multilineage dysplasia (RCMD), which requires monocytes <1×10⁹/L by definition 6
• Myeloproliferative neoplasms (MPN) with monocytosis 4
• Acute myeloid leukemia - when blast percentage is elevated 5

Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Recent evidence shows that clonal hematopoiesis mutations occur more frequently in older individuals with monocytosis (50.9% vs 35.5% in controls) 7. However, monocytosis plus CHIP does not automatically indicate malignancy - only 30% maintain persistent monocytosis over 4 years, and myeloid malignancies developed in only 4/167 cases studied 7.

Key distinction: Monocytosis with isolated DNMT3A, TET2, or ASXL1 mutations (typical age-related CHIP) is NOT significantly associated with clonal monocytic proliferation. However, multiple gene mutations or spliceosome mutations ARE associated with true clonal monocytosis 7.

Algorithmic Diagnostic Approach

Step 1: Confirm True Monocytosis

• Verify by manual differential count under microscope by experienced observer 4
• Exclude cytological mimics: hairy cells, promonocytes, monoblasts
• Threshold: ≥1×10⁹/L AND ≥10% of leukocytes (traditional); newer classifications use ≥0.5×10⁹/L for CMML 8

Step 2: Identify or Exclude Reactive Causes

• Complete history focusing on infections, inflammatory conditions, solid tumors 5
• Physical examination: splenomegaly, cutaneous lesions, lymphadenopathy
• Laboratory: inflammatory markers (CRP, ESR), infectious workup as indicated
• If reactive cause identified and monocytosis resolves with treatment → diagnosis complete

Step 3: If Persistent Without Reactive Cause → Investigate for Clonal Disorder

Required investigations 5:

• Complete blood count with differential - assess for cytopenias, other cell line abnormalities
• Peripheral blood smear - evaluate dysplasia, blast percentage, immature cells
• Bone marrow aspiration and biopsy - assess dysplasia, blast percentage, cellularity
• Conventional cytogenetics - identify clonal abnormalities (most common: chromosome 7 abnormalities, trisomy 8)
• Molecular testing:
  • BCR-ABL1 to exclude chronic myeloid leukemia
  • PDGFRA/PDGFRB rearrangements (mandatory if eosinophilia present)
  • Store sample for potential mutation analysis (TET2, SRSF2, ASXL1, NRAS, KRAS, CBL, JAK2) 5

Optional but helpful 4, 9:

• Flow cytometry monocyte subset analysis - classical monocytes >94% supports CMML diagnosis
• Immunophenotyping - detect aberrant antigen expression (CD11b/HLA-DR, CD36/CD14 abnormalities, CD56 overexpression)

Step 4: Longitudinal Observation if Borderline

• If monocytosis is mild and no definitive clonal features identified, observe for ≥3 months 5
• Repeat complete blood count and bone marrow evaluation if monocytosis persists
• Monitor for development of cytopenias, splenomegaly, or constitutional symptoms

Critical Pitfalls to Avoid

1. Assuming all monocytosis in elderly is CHIP/benign - While CHIP is common with aging, persistent monocytosis with multiple mutations or spliceosome mutations warrants closer surveillance 7

2. Missing PDGFRA/PDGFRB rearrangements in eosinophilia cases - These require specific targeted therapy and are excluded from CMML diagnosis 5

3. Relying solely on flow cytometry without morphology - Flow abnormalities are supportive but not diagnostic without morphologic dysplasia or cytogenetic abnormalities 6

4. Inadequate exclusion of reactive causes - Must specifically investigate infections, solid tumors, and inflammatory conditions before diagnosing clonal disorder 5, 4

5. Misclassifying cells on automated differential - Manual review by experienced observer is essential to avoid counting hairy cells, promonocytes, or monoblasts as monocytes 4